a2 Cont

Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

a3

12. (Amended) Use of a polypeptide according to claim 9 wherein a degenerative disorder is a degenerative disorder of the central nervous system.

a4

16. (Amended) Use of a polypeptide according to claim 15 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

17. (Amended) Use of a polypeptide according to claim 9 wherein the polypeptide is synthetic.

a5

20. (Amended) A method according to claim 18 wherein the animal is a mammal.

a6

22. (Amended) A method according to claim 18 wherein the neurodegenerative disorder is a degenerative disorder of the central nervous system.

a7

26. (Amended) A method according to claim 24 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

27. (Amended) A method according to claim 18 wherein the mutation results in a truncated product from the PKCγ gene being produced.

a8

30. (Amended) A method according to claim 18 wherein detection of the presence of the mutation in the PKCγ gene is achieved by detecting altered levels of the mRNA transcripts or mRNA precursor.

31. (Amended) A method according to claim 18 wherein the mutation in the PKCγ gene is detected using antibodies raised to the truncated PKC type I polypeptide.

a9

41. (Amended) An antibody according to claim 38 wherein the antibody is a monoclonal antibody.

a10

43. (Amended) Use of an antibody according to claim 38 for the manufacture of a medicament for preventing, delaying, treating or inhibiting degeneration of the nervous system.

44. (Amended) Use of an antibody according to claim 38 in a diagnostic assay for testing an human thought to have or be predisposed to having a neural degenerative disorder.

Abstract:

At page 58, the page following the claims, please insert –The present invention relates to the use of a polynucleotide fragment comprising PKCγ gene including type 1 subtype of protein kinase C in the manufacture of a medicament for treating a neurodegenerative disorder. The invention further relates to use of a polypeptide which comprises protein kinase C type 1 in the manufacture of a medicament for treating a neurodegenrative disorder. Further disclosed is a method of testing an animal, such as human, thought to have or be predisposed to having a neurodegenerative disorder which comprises detecting the presence of a mutation in PKCγ gene and/or its associated promoter.

a11